Bellerophon Therapeutics, Inc. (BLPH) Sees Unusually-High Trading Volume
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) saw unusually-high trading volume on Tuesday . Approximately 1,794,481 shares changed hands during trading, an increase of 550% from the previous session’s volume of 276,083 shares.The stock last traded at $1.18 and had previously closed at $1.13.
BLPH has been the subject of a number of recent research reports. ValuEngine lowered shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 10th. Zacks Investment Research lowered shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 22nd.
The firm’s 50-day moving average is $1.24 and its 200-day moving average is $1.36. The stock’s market capitalization is $41.90 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. On average, equities research analysts anticipate that Bellerophon Therapeutics, Inc. will post ($1.12) earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in BLPH. Renaissance Technologies LLC raised its position in Bellerophon Therapeutics by 330.8% in the fourth quarter. Renaissance Technologies LLC now owns 239,100 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 183,600 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in Bellerophon Therapeutics in the first quarter worth $125,000. Vanguard Group Inc. raised its position in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after acquiring an additional 211,111 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in Bellerophon Therapeutics in the second quarter worth $1,316,000. Hedge funds and other institutional investors own 45.85% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.